Beta Bionics, Inc. (BBNX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$15.18

From 52W high−49.86%

Volume271300.00

Market cap$872.05M

P/E (TTM)—

P/S (TTM)6.9x

Div yield—

Key dataNov 4, 2026

Open

$15.18

From 52W high

−49.86%

Volume

271300.00

Market cap

$872.05M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.7x

P/E (TTM)

—

RSI (14)

36.9

MomentumView details →

1D Return

+6.23%

YTD Return

−49.28%

SummaryUpdated Sep 1, 2026

Beta Bionics, Inc. (NASDAQ:BBNX) is a commercial-stage medical device company founded in 2015 and based in Irvine, California. The company specializes in developing automated insulin delivery systems for people with diabetes, with its flagship product being the <b>iLet Bionic Pancreas</b>. Beta Bionics went public on January 30, 2025, representing a significant milestone for the company as it transitions from development to commercial expansion in the diabetes management market.

Ask drillr about Beta Bionics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.7x

EV/Sales

5.0x

P/S (TTM)

6.9x

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

58.63%

Net Margin

−65.31%

EBITDA Margin

−65.38%

ROE (TTM)

−20.71%

ROA (TTM)

−18.73%

Asset Turnover

0.35x

GrowthView details →

Revenue YoY

+43.69%

EPS YoY

+9.66%

FCF YoY

−8.97%

Revenue CAGR 3Y

+724.29%

EPS CAGR 3Y

−41.41%

EBITDA YoY

−10.38%

MomentumView details →

1D Return

+6.23%

YTD Return

−49.28%

1Y Return

−44.43%

RSI (14)

36.9

vs 50D SMA

−18.48%

vs 200D SMA

+4.47%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

8.92x

Quick Ratio

8.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

0.64%

Beats (12Q)

5/12

Next Q EPS Est

−$0.50

Avg Surprise (4Q)

11.38%

Rev Surprise

2.26%

Financials snapshotView financials →

Revenue (TTM)

127.27M

Net Income (TTM)

−83.12M

Op. CF (TTM)

−59.37M

Next earningsMar 30, 2027 →

Latest newsMore news →

A lawsuit alleges that Beta Bionics, Inc. failed to disclose key facts to investors between July 30, 2025 and February 24, 2026.8d ago

Law Offices of Frank R. Cruz announced a class action lawsuit against Beta Bionics, Inc. on behalf of investors who acquired its securities from July 30, 2025, to February 24, 2026, alleging misleading statements.9d ago

Similar companies

艾隆科技688329.SH Brainaurora-b06681.HK Envista Holdings CorpNVST Concentra Group Holdings Parent, Inc.CON Hims & Hers Health, Inc.HIMS Nakamoto Inc.NAKA Find similar companies →

Latest newsMore news →

A lawsuit alleges that Beta Bionics, Inc. failed to disclose key facts to investors between July 30, 2025 and February 24, 2026.8d ago Law Offices of Frank R. Cruz announced a class action lawsuit against Beta Bionics, Inc. on behalf of investors who acquired its securities from July 30, 2025, to February 24, 2026, alleging misleading statements.9d ago HAGENS BERMAN SOBOL SHAPIRO LLP announced that November 3, 2026, was the deadline to seek appointment as lead plaintiff in the proposed investor lawsuit against Beta Bionics, Inc..19d ago